Literature DB >> 7633952

Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient.

J Scholz1, M Schulz, M Steinfath, S Höver, H Bause.   

Abstract

Fluconazole is effective for the treatment of fungal infections. A continuous venovenous hemofiltration (CVVH) was necessary in a liver transplant patient with anuria. Fluconazole treatment was started after the diagnosis of systemic candidiasis. There was no adverse effect on liver function, and the immunosuppression with cyclosporine was not affected. It is shown for the first time that CVVH effectively removes fluconazole from the blood circulation by a clearance into the hemofiltrate of approximately 21 ml/min. These data suggest that the treatment of fungal infections with fluconazole does not necessitate a reduction of the dosage during CVVH.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7633952     DOI: 10.1007/bf00198243

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  12 in total

1.  Rapid determination of serum levels of a new antifungal agent, fluconazole, by high-performance liquid chromatography.

Authors:  K K Hosotsubo; H Hosotsubo; M K Nishijima; T Okada; N Taenaka; I Yoshiya
Journal:  J Chromatogr       Date:  1990-07-13

2.  Fluconazole: a position statement by the Society of Infectious Diseases Pharmacists.

Authors: 
Journal:  Ann Pharmacother       Date:  1992-06       Impact factor: 3.154

Review 3.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

4.  Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  D Debruyne; J P Ryckelynck; M Moulin; B Hurault de Ligny; B Levaltier; M C Bigot
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

5.  Ketoconazole, cyclosporin metabolism, and renal transplantation.

Authors:  R M Ferguson; D E Sutherland; R L Simmons; J S Najarian
Journal:  Lancet       Date:  1982-10-16       Impact factor: 79.321

Review 6.  Secondary mycosis in surgery: treatment with fluconazole.

Authors:  P Kujath; K Lerch
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

7.  Absence of significant interaction of fluconazole with cyclosporin.

Authors:  H U Krüger; U Schuler; R Zimmermann; G Ehninger
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

Review 8.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

9.  Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy.

Authors:  E Anaissie; G P Bodey; H Kantarjian; C David; K Barnett; E Bow; R Defelice; N Downs; T File; G Karam
Journal:  Am J Med       Date:  1991-08       Impact factor: 4.965

10.  An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole.

Authors:  S Toon; C E Ross; R Gokal; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

View more
  2 in total

Review 1.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

2.  Pharmacokinetics and Pharmacodynamics of Anti-infective Agents during Continuous Veno-venous Hemofiltration in Critically Ill Patients: Lessons Learned from an Ancillary Study of the IVOIRE Trial.

Authors:  Dominique Breilh; Patrick M Honore; David De Bels; Jason A Roberts; Jean Baptiste Gordien; Catherine Fleureau; Antoine Dewitte; Julien Coquin; Hadrien Rozé; Paul Perez; Rachid Attou; Sebastien Redant; Luc Kugener; Marie-Claude Saux; Herbert D Spapen; Alexandre Ouattara; Olivier Joannes-Boyau
Journal:  J Transl Int Med       Date:  2019-12-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.